These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 31066805)
1. Moderate to severe plaque psoriasis - treatment with drugs of the classic scheme. Arnone M; Carvalho AVE; Takahashí MDF; Bernardo WM Rev Assoc Med Bras (1992); 2019 May; 65(4):530-534. PubMed ID: 31066805 [TBL] [Abstract][Full Text] [Related]
2. Psoriasis in moderate grave plaque - immunobiological treatment. Arnone M; Carvalho AVE; Takahashi MDF; Bernardo WM Rev Assoc Med Bras (1992); 2019 May; 65(4):493-508. PubMed ID: 31066801 [TBL] [Abstract][Full Text] [Related]
3. Use of infliximab in the treatment of psoriasis. Lee MR; Cooper AJ Australas J Dermatol; 2004 Aug; 45(3):193-5. PubMed ID: 15250904 [No Abstract] [Full Text] [Related]
5. [News on psoriasis from the 2010 Dermatology Days in Paris]. Boulinguez S Ann Dermatol Venereol; 2011 May; 138(5 Suppl 1):H1-5. PubMed ID: 21703458 [No Abstract] [Full Text] [Related]
6. Conventional therapies for psoriasis. Rebora A Reumatismo; 2007; 59 Suppl 1():77-80. PubMed ID: 17828351 [TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study. Ergun T; Seckin Gencosmanoglu D; Alpsoy E; Bulbul-Baskan E; Saricam MH; Salman A; Onsun N; Sarioz A J Dermatol; 2017 Jun; 44(6):630-634. PubMed ID: 27943425 [TBL] [Abstract][Full Text] [Related]
9. Combination of adalimumab with traditional systemic antipsoriatic drugs - a report of 39 cases. Philipp S; Wilsmann-Theis D; Weyergraf A; Rotterdam S; Frambach Y; Gerdes S; Mössner R J Dtsch Dermatol Ges; 2012 Nov; 10(11):821-37. PubMed ID: 22934607 [TBL] [Abstract][Full Text] [Related]
10. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. Bronckers IMGJ; Seyger MMB; West DP; Lara-Corrales I; Tollefson M; Tom WL; Hogeling M; Belazarian L; Zachariae C; Mahé E; Siegfried E; Philipp S; Szalai Z; Vleugels RA; Holland K; Murphy R; Baselga E; Cordoro K; Lambert J; Alexopoulos A; Mrowietz U; Kievit W; Paller AS; JAMA Dermatol; 2017 Nov; 153(11):1147-1157. PubMed ID: 28903160 [TBL] [Abstract][Full Text] [Related]
11. A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents. Ortiz A; Yamauchi PS Skinmed; 2006; 5(6):285-8. PubMed ID: 17085995 [TBL] [Abstract][Full Text] [Related]
12. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions. Opmeer BC; Heydendael VM; deBorgie CA; Spuls PI; Bossuyt PM; Bos JD; de Rie MA J Clin Epidemiol; 2007 Jul; 60(7):696-703. PubMed ID: 17573985 [TBL] [Abstract][Full Text] [Related]
13. [Long-term control of psoriasis is necessary]. Sánchez Carazo JL; Martínez Casimiro L; Alegre de Miguel V Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():29-36. PubMed ID: 18341851 [TBL] [Abstract][Full Text] [Related]
14. Crohn's disease - treatment with biological medication. Zaltman C; Amarante H; Brenner MM; Costa MHM; Flores C; Leal RF; Grain JFS; Zeroncio M Rev Assoc Med Bras (1992); 2019 May; 65(4):554-567. PubMed ID: 31066809 [TBL] [Abstract][Full Text] [Related]
15. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists. Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995 [No Abstract] [Full Text] [Related]
16. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study. Gottlieb AB; Kalb RE; Blauvelt A; Heffernan MP; Sofen HL; Ferris LK; Kerdel FA; Calabro S; Wang J; Kerkmann U; Chevrier M J Am Acad Dermatol; 2012 Oct; 67(4):642-50. PubMed ID: 22153792 [TBL] [Abstract][Full Text] [Related]
17. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Naldi L; Griffiths CE Br J Dermatol; 2005 Apr; 152(4):597-615. PubMed ID: 15840088 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of psoriasis. O'Rielly DD; Rahman P Pharmacogenomics; 2011 Jan; 12(1):87-101. PubMed ID: 21174624 [TBL] [Abstract][Full Text] [Related]
19. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Smith EC; Riddle C; Menter MA; Lebwohl M Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874 [TBL] [Abstract][Full Text] [Related]
20. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]